DE1467875A1 - Verfahren zur Herstellung von Darmmedikamenten - Google Patents
Verfahren zur Herstellung von DarmmedikamentenInfo
- Publication number
- DE1467875A1 DE1467875A1 DE19621467875 DE1467875A DE1467875A1 DE 1467875 A1 DE1467875 A1 DE 1467875A1 DE 19621467875 DE19621467875 DE 19621467875 DE 1467875 A DE1467875 A DE 1467875A DE 1467875 A1 DE1467875 A1 DE 1467875A1
- Authority
- DE
- Germany
- Prior art keywords
- τοη
- maleic anhydride
- ester
- soluble
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 63
- 230000000968 intestinal effect Effects 0.000 title claims description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 20
- 229940079593 drug Drugs 0.000 claims description 47
- 150000002148 esters Chemical class 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- 230000003111 delayed effect Effects 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 33
- 210000000936 intestine Anatomy 0.000 description 29
- 239000000126 substance Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 15
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
- 150000008064 anhydrides Chemical class 0.000 description 12
- -1 ethylene compound Chemical class 0.000 description 11
- 238000007922 dissolution test Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YYXLGGIKSIZHSF-UHFFFAOYSA-N ethene;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1 YYXLGGIKSIZHSF-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 125000003158 alcohol group Chemical group 0.000 description 8
- 239000004927 clay Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- MRAKLTZPBIBWFH-ARJAWSKDSA-N (z)-2-ethenylbut-2-enedioic acid Chemical compound OC(=O)\C=C(\C=C)C(O)=O MRAKLTZPBIBWFH-ARJAWSKDSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004641 Diallyl-phthalate Substances 0.000 description 2
- 101100420683 Drosophila melanogaster Sarm gene Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000005076 polymer ester Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YAWWQIFONIPBKT-HXUWFJFHSA-N 2-[[(2r)-2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3h-inden-5-yl]oxy]acetic acid Chemical compound C1([C@@]2(C(C3=C(Cl)C(Cl)=C(OCC(O)=O)C=C3C2)=O)CCCC)CCCC1 YAWWQIFONIPBKT-HXUWFJFHSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015047 pilsener Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US140201A US3143472A (en) | 1961-09-25 | 1961-09-25 | Enteric compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1467875A1 true DE1467875A1 (de) | 1969-01-23 |
Family
ID=22490185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19621467875 Pending DE1467875A1 (de) | 1961-09-25 | 1962-09-24 | Verfahren zur Herstellung von Darmmedikamenten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3143472A (en, 2012) |
| BE (1) | BE622793A (en, 2012) |
| CH (1) | CH435562A (en, 2012) |
| CY (1) | CY486A (en, 2012) |
| DE (1) | DE1467875A1 (en, 2012) |
| DK (1) | DK103796C (en, 2012) |
| ES (1) | ES280881A1 (en, 2012) |
| GB (1) | GB1024648A (en, 2012) |
| NL (2) | NL283570A (en, 2012) |
| OA (1) | OA03371A (en, 2012) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3325365A (en) * | 1963-04-02 | 1967-06-13 | Ciba Geigy Corp | Enteric composition for tablet compression coating |
| US3407157A (en) * | 1965-05-19 | 1968-10-22 | Hoffmann La Roche | Tablet coating compositions comprising methyl vinyl ethermaleic anhydride copolymer,plasticizer and surface active agent |
| NL6612024A (en, 2012) * | 1966-08-26 | 1968-02-27 | ||
| US3914401A (en) * | 1971-10-12 | 1975-10-21 | Lilly Co Eli | Enteric compositions |
| US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
| US3971367A (en) * | 1972-12-27 | 1976-07-27 | Alza Corporation | Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape |
| US4180064A (en) * | 1972-12-27 | 1979-12-25 | Alza Corporation | System for delivering agent to environment of use over prolonged time |
| US3898986A (en) * | 1972-12-27 | 1975-08-12 | Alza Corp | Biotransformable intrauterine device |
| US3914402A (en) * | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
| US4014987A (en) * | 1974-06-04 | 1977-03-29 | Alza Corporation | Device for delivery of useful agent |
| US4088798A (en) * | 1975-11-11 | 1978-05-09 | Sandoz, Inc. | Methods for the preparation of controlled gastric residence time medicament formulations |
| US4261969A (en) * | 1979-05-03 | 1981-04-14 | World Health Organization | Controlled drug release composition |
| US4249531A (en) * | 1979-07-05 | 1981-02-10 | Alza Corporation | Bioerodible system for delivering drug manufactured from poly(carboxylic acid) |
| FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4960765A (en) * | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| WO1981002671A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
| US4381772A (en) * | 1980-11-20 | 1983-05-03 | Guistini Fernando G | Bioerodible diaphragm |
| GB2285989A (en) * | 1994-01-28 | 1995-08-02 | Merck Frosst Canada Inc | Aqueous formulations for enteric coatings |
| CN1084664C (zh) * | 1998-08-05 | 2002-05-15 | 纪正德 | 鞋体中底板的制造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL42671C (en, 2012) * | 1932-11-23 | |||
| CH283585A (de) * | 1950-03-15 | 1952-06-15 | Hoffmann La Roche | Zur Herstellung von Tablettenüberzügen geeignetes Gemisch. |
| US2897122A (en) * | 1956-10-04 | 1959-07-28 | Frosst & Co Charles E | Enteric coated product |
| US2897121A (en) * | 1957-06-04 | 1959-07-28 | Upjohn Co | Pharmaceutical composition |
| US2957804A (en) * | 1958-06-06 | 1960-10-25 | Harlan R Shuyler | Pesticide |
| US2954323A (en) * | 1958-10-06 | 1960-09-27 | Abbott Lab | Thin film coating for tablets and the like |
| US3070509A (en) * | 1958-12-18 | 1962-12-25 | Roehm & Haas Gmbh | Process for coating medicaments |
| US2993837A (en) * | 1959-07-13 | 1961-07-25 | Frosst & Co Charles E | Enteric coated tablets |
| US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
-
0
- BE BE622793D patent/BE622793A/xx unknown
- NL NL121337D patent/NL121337C/xx active
- NL NL283570D patent/NL283570A/xx unknown
-
1961
- 1961-09-25 US US140201A patent/US3143472A/en not_active Expired - Lifetime
-
1962
- 1962-09-18 ES ES280881A patent/ES280881A1/es not_active Expired
- 1962-09-24 DE DE19621467875 patent/DE1467875A1/de active Pending
- 1962-09-24 GB GB36179/62A patent/GB1024648A/en not_active Expired
- 1962-09-24 DK DK414062AA patent/DK103796C/da active
- 1962-09-24 CH CH1123862A patent/CH435562A/de unknown
-
1967
- 1967-03-30 OA OA52866A patent/OA03371A/xx unknown
-
1969
- 1969-04-29 CY CY48669A patent/CY486A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA03371A (fr) | 1970-12-15 |
| CY486A (en) | 1969-04-29 |
| GB1024648A (en) | 1966-03-30 |
| CH435562A (de) | 1967-05-15 |
| NL121337C (en, 2012) | |
| NL283570A (en, 2012) | |
| BE622793A (en, 2012) | |
| US3143472A (en) | 1964-08-04 |
| ES280881A1 (es) | 1963-02-01 |
| DK103796C (da) | 1966-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1467875A1 (de) | Verfahren zur Herstellung von Darmmedikamenten | |
| DE2031871C3 (de) | Überzugsmasse für Arzneiformen | |
| DE69310461T2 (de) | Weiche Kapseln mit Magensaftresistentem Überzug und Verfahren zu ihrer Herstellung | |
| DE3786316T2 (de) | Überzugsmembran und damit hergestellte Mittel. | |
| EP0164669B1 (de) | Verfahren zum Überziehen von Arzneiformen | |
| DE69107686T2 (de) | Im Dickdarm zersetzbare Hartkapseln. | |
| DE69002604T2 (de) | Pharmazeutische Zubereitung mit verzögerter Freisetzung und seine Herstellung. | |
| DE60202662T2 (de) | NEUE FILMBESCHICHTUNG enthaltend ein Äthylacrylate/Methylmethacrylate-copolymer und Polyvinylacetat | |
| DE19541333C2 (de) | Beschichtungsgrundlage für feste pharmazeutische Darmpräparate | |
| DD237611A5 (de) | Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimittel | |
| DE1467781A1 (de) | Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe | |
| DE69225979T2 (de) | Orale zubereitung zur freisetzung im unteren verdauungstract | |
| CH629386A5 (de) | Fuer die orale verabreichung bestimmtes granulat eines arzneimittels. | |
| DE2812817A1 (de) | Polymer mit ph-abhaengiger loeslichkeit, verfahren zu dessen herstellung und dessen verwendung | |
| DE2528190B2 (de) | Verfahren zum Beschichten von festen Arzneiformen | |
| DE2247060A1 (de) | Arzneibeschichtungsmittel und verfahren zur herstellung von beschichteten arzneimitteln | |
| DE1219175B (de) | Verfahren zur Herstellung von gegen die Einwirkung von Pansensaeften der Wiederkaeuer geschuetzten Wirkstoffzubereitungen | |
| DE2035739A1 (en) | Oral enzyme prepsn - consisting of granulate with gastric juices-resistant coating in tablet or capsule form | |
| DE3421860C2 (de) | Verfahren zum Überziehen von Arzneiformen | |
| DE19741114C2 (de) | Feuchtigkeitsstabile und magensaftresistente Arzneiform für Fische | |
| DE2250028A1 (de) | Enterische zusammensetzungen | |
| EP0050191B1 (de) | Verfahren zur Herstellung eines umhüllten Acetylsalicylsäurepräparates | |
| DE1467875C (de) | Verwendung eines darmlöslichen Partialesters eines Mischpolymerisats zur Umhüllung von Darmarzneimitteln | |
| DE1492117B2 (de) | Verfahren zur herstellung von modifizierten polyvinylalkoholen und deren verwendung als ueberzuege auf pharmazeutischen praeparaten | |
| AT256339B (de) | Verfahren zur Herstellung magensaftbeständiger, darmlöslicher, fester pharmazeutischer Formen |